(Health Times, Zhang Meng)
According to the incomplete statistics of Health Times, in the past 2021, a number of pharmaceutical companies have made major personnel adjustments, and the heads of major business departments of more than 30 pharmaceutical companies have left or been transferred. Not only that, this year, there are also a number of well-known multinational pharmaceutical companies in China to change coaches.
Xi'an Janssen: President Ansgart was transferred to the position of Managing Director of Emerging Markets in Europe, the Middle East and Africa
Asgar Rangoonwala
On March 29, 2021, Johnson & Johnson's pharmaceutical company, Xi'an Janssen, announced that from April 1, Ms. Zheng Lei will take over as President of Xi'an Janssen, and the former President Ansgart will serve as Managing Director of Janssen Emerging Markets in Europe, the Middle East and Africa.
Ansgart is a Janssen veteran who joined Janssen in Germany more than 20 years ago and was transferred from Managing Director of Janssen Turkey to President of Xi'an Janssen Pharmaceutical Co., Ltd. in 2016. Over the past few years, Ansgart has led Xi'an Janssen to successfully obtain 27 new products and indications in China, and has included 52 innovative drugs in the national medical insurance directory.
Huizhi Pharmaceutical: Miao Tianxiang, Chairman of Greater China, retires from office
Miao Tianxiang
In early June 2021, Miao Tianxiang, chairman of Huizhi Pharmaceutical Greater China, retired.
In May 2018, Tianxiang Miao took over as President of Pfizer Core Healthcare Greater China and Country Manager of Pfizer China. With a series of adjustments to the internal structure, Huizhi was officially established in November 2020. Miao Tianxiang became the chairman of Huizhi Greater China. Prior to that, Tianxiang Miao's position was CFO of Pfizer Greater China. In 1994, Miao Tianxiang joined Pfizer China. In 2014, he was appointed CFO of Pfizer China, becoming the first Chinese mainland person in the history of Pfizer China to be appointed as a CFO. During his time at Pfizer, Tianxiang Miao held a range of increasingly important positions in a number of departments including animal health, manufacturing and pharmaceutical business.
Bayer: Greater China President Wei Jiang retired from his post
Jiang Wei
On June 2, Bayer China announced that due to family arrangements, Jiang Wei, member of the Global Executive Committee of Bayer Group's Prescription Drugs Division, global executive vice president and president of China and Asia Pacific, and president of Bayer Group Greater China, will retire. Wei Jiang will continue to serve as President of Bayer Group Greater China and will be responsible for the Asia Pacific region until 30 September 2021.
According to the news, from July 1, 2021, Zhou Xiaolan, currently senior vice president of Bayer Group's Prescription Drugs Division and President of Asia Pacific, will take over as a member of the Global Executive Committee of Bayer Group's Prescription Drugs Division and President of China. Chen Ying, Senior Vice President of Bayer Group's Prescription Drugs Division and Head of Marketing in China, will take over as President of Bayer Group's Prescription Drugs Division Asia Pacific.
Merck: China President Lo Wanli leaves office
Rovanli
On July 14, 2021, Jixing Pharmaceutical announced the appointment of Mr. Joseph Romanelli as the Company's Chief Executive Officer and Board Member, effective immediately. In his appointment, Mr. Luo Wanli will be responsible for the development of Etripamil, a licensed drug recently announced by Mistar for the treatment of paroxysmal supraventricular tachycardia (PSVT) and other indications for cardiovascular disease, in Greater China.
Just before that, Merck China announced that Lo Wanli would resign as President of Merck China on June 1 to become President of Merck USA. After The departure of Lo Wanli, Anna Tian, currently president and managing director of MERCK Canada, will take over the current role of Lo Wanli. A month later, Rowany left Merck.
Mr. Lo joined MSD in 1996, served as General Manager of MSD China hong Kong from 2012 to 2013, General Manager of MSD Taiwan in 2015, and President of MSD China in 2016, making MSD China the second largest market in the world and ranked among the top 3 multinational pharmaceutical companies in China in terms of sales.
It is understood that Jixing Pharmaceutical was founded by RTW, a well-known investment company in the pharmaceutical industry in New York, dedicated to the development of innovative therapies for major diseases, and its most concerned products are the small molecule myocardial myoglobulin inhibitor CK-274 licensed by Cytokinetics, and the PSVT drug Etripamil, which just reached a cooperation agreement with Milestone in Greater China in May this year. Both products are currently in clinical trials.
Roche: China President Zhou Hong left and joined Merck
Zhou Hong
On July 23, 2021, Merck's official website announced that Ms. Zhou Hong will assume the position of Head of China and International Markets of Merck Group's Pharmaceuticals and Healthcare from October 1. Prior to joining Merck, Zhou Hong officially joined Roche in March 2015 as president of Roche Pharma China, and in the past six and a half years, she led Roche Pharmaceuticals to double its sales in China and brought great benefits to Chinese patients.
According to Merck's official website, Zhou Hong will lead teams in China, Japan, as well as Europe, Latin America, Asia Pacific, the Middle East, Africa and Russia, and will be responsible for the global endocrine, cardiovascular and metabolic (CM&E) product line and global business innovation business, reporting to Peter Guenter, member of merck group's executive board and CEO of the pharmaceutical and health business. She will also be a member of merck Pharma's global management team and is based in Shanghai, China.
After Zhou Hong leaves Roche, that is, from October 1, 2021, her position will be taken over by Bian Xin. Bian Xin joined Roche Pharma in April 2019 and is currently Vice President of Market Access for Roche Pharma, and prior to joining Roche Pharma, Bian Xin served as Vice President of Xi'an Janssen, Head of Innovative Products Business Unit, and Chief Commercial Officer of BeiGene.
Amgen: Xu Took over as General Manager of China
Xu Qiling
In August 2021, Amgen announced the official appointment of Ms. Xu Aering as Amgen's Vice President and General Manager of China. Prior to joining Amgen, Mr. Xu held leadership positions in various regional markets of Janssen Pharmaceuticals and Roche Pharmaceuticals.
Previously, the position was held by Meiling Ke (currently Vice President and General Manager of Amgen Asia Pacific). Ms. Ke joined Amgen in 2011 and previously had nearly 10 years of experience at Ms. Merck. In February 2019, Ke Meiling was appointed Vice President and General Manager of Amgen China. In November 2020, Ms. Ke was promoted to Vice President and General Manager of Amgen Asia Pacific, while also serving as General Manager of China until a new successor takes office.
Pfizer: Peng Zhenke takes over as President of China
Peng Zhenke
On September 1, 2021, Peng Zhenke officially assumed the role of President of Pfizer Biopharmaceutical Group China, and Pierre Gaudreault, former President of Pfizer China, returned to the position of President of Emerging Markets Asia.
Peng Zhenke is a star among the executives of multinational pharmaceutical companies in China, and he has served as an executive of well-known multinational pharmaceutical companies such as Bristol-Myers Squibb and Sanofi. It is worth mentioning that more than 20 years ago, Peng Zhenke was a member of Pfizer, serving as a senior product manager of Lipitor from March 1997 to February 2000, and led Lipitor to create a sales legend in the history of Pfizer's drug development.
Xerox: Hu Hai takes over as General Manager of Greater China
On September 27, 2021, medical device orthopedic giant Xerox Fawer officially announced that Xerox Brilliance Greater China Managing Director An Mingde will leave the company, and Hu Hai from Johnson & Johnson Orthopedics joined Xerox Röder as General Manager of Xerox Greater China since September 27.
According to public information, Hu Hai has more than 20 years of experience in the medical technology industry, and before joining Xerox, Hu Hai was the china vice president of Johnson & Johnson Orthopedics Company Depuy Synthes. Prior to that, between 1999 and 2008, Hu held various management positions at GE Healthcare.
Stryker: Min Ma, General Manager of China, is a consultant and Greg Holman is appointed President of China
On October 13, 2021, device giant Stryker announced to employees that it has appointed Greg Holman as its new president of China, effective immediately. Ma Min, the former general manager of Stryker China, will continue to serve stryker as a consultant. Min Ma has been CEO of Stryker China since November 2017, and prior to joining Stryker, Min Ma was Vice President of MITTG in Medtronic Greater China.
Fresenius Kabi: China President Ding Weibo leaves office
Ding Weibo
In December 2021, Fresenius Scarbi, a leading company in the field of infusion, blood transfusion and clinical nutrition, announced that China President Ding Weibo will leave on February 1, 2022 due to his decision to accept external development opportunities. Ulf Jansson, Executive Vice President of Fresenius Scarbi Asia Pacific, will also serve as President of Fresenius Scarby China. It is reported that before Ding Weibo joined Fresenius Kabi, he had worked for many years in Janssen, Sino-American Squibb and Novartis.
Pfizer: Wu Kun, Chief Operating Officer of China, leaves office
Wu Kun
On December 30, 2021, Pfizer China announced that Chief Operating Officer Kun Wu kun will be leaving Pfizer, with the last working day being December 31, 2021. In the afternoon of the same day, Wu Kun also issued a farewell email to Pfizer China employees, officially confirming the news, saying that after 26 years of work at Pfizer, he will leave Pfizer, and tomorrow (December 31) is the last working day.
Kun joined Pfizer in 1995 and was appointed General Manager of Pfizer China Acute Care Business Group in 2014. Since 2019, after the adjustment of Pfizer's global organizational structure and formal division into three major business groups of biopharmaceuticals, puqiang and health drugs, Wu Kun has become the general manager of Pfizer Biopharmaceutical (PBG) China.
At the end of 2019, Wu Kun briefly left Pfizer, but then Susan Silberman, global president of Pfizer Emerging Markets, announced that after further thinking and sincere retention of the team, Wu Kun decided to stay in the company as the chief operating officer of Pfizer Biopharmaceutical Group China.